stocks index  markets index bulletin investor alert new york markets close in market snapshot winners and losers stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pall the companies in jeff bezos’s empire in one large chart pbaker hughes data show weekly us oilrig count up a third time this month pamazon’s postearnings stock selloff is the smallest in seven years peuropean stocks end at month low as ubs falls tech worries weigh psurging australian dollar makes life tough for central bankers pus weekly active oilrig count up  at  baker hughes pus total weekly active drillingrig count up  at  baker hughes pseptember wti oil trades at bbl little changed from before the rig data pwhy the sec’s crackdown could be good for initial coin offerings pmattel shares down  in friday trading pexpedia stock price target raised to  from  at ubs paarons shares up  in friday trading pwhere healthcare reform goes after failure to repeal and replace obamacare psp  down  points or  at  pdow industrials down  points at  pbreakingnasdaq pares losses down  points at  pftse  closes sharply lower in tobaccoled stock rout phere’s how much you should spend on a yoga mat and why you should always use your own phow advisers can fight the ‘crisis of trust’ in financial services phow venezuela chaos could spark oil rally opec has failed to achieve loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stocks index  markets index bulletin investor alert new york markets close in market snapshot winners and losers stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pall the companies in jeff bezos’s empire in one large chart pbaker hughes data show weekly us oilrig count up a third time this month pamazon’s postearnings stock selloff is the smallest in seven years peuropean stocks end at month low as ubs falls tech worries weigh psurging australian dollar makes life tough for central bankers pus weekly active oilrig count up  at  baker hughes pus total weekly active drillingrig count up  at  baker hughes pseptember wti oil trades at bbl little changed from before the rig data pwhy the sec’s crackdown could be good for initial coin offerings pmattel shares down  in friday trading pexpedia stock price target raised to  from  at ubs paarons shares up  in friday trading pwhere healthcare reform goes after failure to repeal and replace obamacare psp  down  points or  at  pdow industrials down  points at  pbreakingnasdaq pares losses down  points at  pftse  closes sharply lower in tobaccoled stock rout phere’s how much you should spend on a yoga mat and why you should always use your own phow advisers can fight the ‘crisis of trust’ in financial services phow venezuela chaos could spark oil rally opec has failed to achieve loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising stockscountryunited states index  markets index bulletin investor alert new york markets close in market snapshot winners and losers stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pall the companies in jeff bezos’s empire in one large chart pbaker hughes data show weekly us oilrig count up a third time this month pamazon’s postearnings stock selloff is the smallest in seven years peuropean stocks end at month low as ubs falls tech worries weigh psurging australian dollar makes life tough for central bankers pus weekly active oilrig count up  at  baker hughes pus total weekly active drillingrig count up  at  baker hughes pseptember wti oil trades at bbl little changed from before the rig data pwhy the sec’s crackdown could be good for initial coin offerings pmattel shares down  in friday trading pexpedia stock price target raised to  from  at ubs paarons shares up  in friday trading pwhere healthcare reform goes after failure to repeal and replace obamacare psp  down  points or  at  pdow industrials down  points at  pbreakingnasdaq pares losses down  points at  pftse  closes sharply lower in tobaccoled stock rout phere’s how much you should spend on a yoga mat and why you should always use your own phow advisers can fight the ‘crisis of trust’ in financial services phow venezuela chaos could spark oil rally opec has failed to achieve loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry fate key statistics  fate therapeutics inc financial ratios  marketwatch bulletin investor alert new york markets close in market snapshot winners and losers expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close fate therapeutics inc nasdaq fate go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus fate therapeutics inc market open  real time quotes jul    pm fate quoteszigmancomposite   change   volume volume  real time quotes quoteszigmancomposite previous close     change   day low day high    week low  week high   company description fate therapeutics inc is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder it programmed cellular therapeutics for the treatment of life threatening diseases hematologic malignancies genetic disorders and diseases resu fate therapeutics inc is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder it programmed cellular therapeutics for the treatment of life threatening diseases hematologic malignancies genetic disorders and diseases resulting from the dysregulation of the immune system the company products include prohema protmune adaptive nk ipscderived nk programmed cd and t cell therapy fate therapeutics was founded by philip beachy sheng ding rudolf jaenisch randall t moon michael rudnicki david scadden leonard zon alexander rives scott wolchko and john d mendlein on april   and is headquartered in san diego ca valuation pe current  pe ratio with extraordinary items  price to sales ratio  price to book ratio  enterprise value to ebitda  enterprise value to sales  total debt to enterprise value  efficiency revenueemployee  income per employee  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure total debt to total equity  total debt to total capital  total debt to total assets  longterm debt to equity  longterm debt to total capital  officers and executives name age officer since title mr j scott wolchko   president chief executive officer  director dr chris m storgard   chief medical officer dr daniel d shoemaker   chief scientific officer mr walter grubb   vice presidentbusiness development dr stewart abbot   chief development officer insider actions – purchase – sale  – number of transactions  date name shares transaction value  william h rastetter director    acquisition at  per share   timothy p coughlin director    acquisition at  per share   chris m storgard chief medical officer    acquisition at  per share   j scott wolchko president and ceo director    derivativenonderivative trans at  per share   j scott wolchko president and ceo director    derivativenonderivative trans at  per share   j scott wolchko president and ceo director    derivativenonderivative trans at  per share   j scott wolchko president and ceo director    award at  per share   daniel d shoemaker chief scientific officer    award at  per share   daniel d shoemaker chief scientific officer    award at  per share   cindy r tahl general counsel and secretary    award at  per share   cindy r tahl general counsel and secretary    award at  per share   stewart abbot chief development officer    award at  per share   stewart abbot chief development officer    award at  per share   j scott wolchko president and ceo director    award at  per share   daniel d shoemaker chief scientific officer    award at  per share   cindy r tahl general counsel and secretary    award at  per share   stewart abbot chief development officer    award at  per share   j scott wolchko president and ceo director    derivativenonderivative trans at  per share   j scott wolchko president and ceo director    derivativenonderivative trans at  per share   christian weyer see remarks director    derivativenonderivative trans at  per share   j scott wolchko president and ceo director    award at  per share   daniel d shoemaker chief scientific officer    award at  per share   christian weyer see remarks director    award at  per share   peter d flynn see remarks    award at  per share   pratik s multani chief medical officer    award at  per share   peter d flynn see remarks    disposition at  per share   peter d flynn see remarks    derivativenonderivative trans at  per share   peter d flynn see remarks    derivativenonderivative trans at  per share   peter d flynn see remarks    derivativenonderivative trans at  per share   peter d flynn see remarks    disposition at  per share   peter d flynn see remarks    derivativenonderivative trans at  per share  newslatestcompanyusfate marketwatch news on fate no news currently available for fate newsnonmarketwatchcompanyusfate other news on fate ecor capital llc buys cytomx therapeutics inc cascadian therapeutics inc fate therapeutics   pm may    gurufocuscom fate therapeutics fate ceo scott wolchko on q  results  earnings call transcript  pm may    seeking alpha fda oks fate therapeutics ind for cancer candidate fatenk shares ahead   am may    seeking alpha q juno therapeutics inc  pm may    edgar online  edg  q k surging earnings estimates signal good news for fate therapeutics fate  am march    zackscom biotech forum daily digest trump proposes changes at fda spotlight on quotient limited  am march    seeking alpha fate therapeutics fate ceo scott wolchko on q  results  earnings call transcript  pm march    seeking alpha k fate therapeutics inc  pm march    edgar online  edg  q k fate therapeutics cleared to begin clinical trial assessing nk cell therapy in blood cancer shares up   am march    seeking alpha zackscom featured highlights apollo investment ballard power systems cymabay therapeutics fate therpautics and oclaro  am march    zackscom explosive stocks under   pm march    zackscom  musthave biotechs for the next  months  pm feb    seeking alpha fate therapeutics fate shares march higher can it continue  am feb    zackscom forget alexion buy these  biotech stocks instead  am feb    zackscom biotech focus near medium and longterm runners  pm feb    seeking alpha the zacks analyst blog highlights gilead sciences celgene fate therapeutics exelixis and akebia therapeutics  am feb    zackscom forget gilead buy these  biotech stocks instead  am feb    zackscom fate therapeutics fate shares march higher can it continue  am jan    zackscom fate therapeutics set to gain momentum in   am jan    seeking alpha biggest movers in manufacturing stocks now – txmd immu life wkhs  am dec    investorplacecom loading more headlines at a glance fate therapeutics inc  general atomics court suite  san diego california  phone   industry biotechnology sector health carelife sciences fiscal yearend  view sec filings revenue m net income m  sales growth  employees  annual report for fate newspressreleasecompanyusfate press releases on fate fate therapeutics reports first quarter  financial results  pm may    globenewswire fate therapeutics announces fda clearance of investigational new drug application for fatenk in advanced solid tumors  am may    globenewswire fate therapeutics to webcast conference call reporting first quarter  financial results  pm may    globenewswire fate therapeutics to kickoff  annual meeting of international society for stem cell research with offtheshelf natural killer cell cancer immunotherapy focus session  am april    globenewswire fate therapeutics to present at the th annual cell  gene therapy investor day  am april    globenewswire fate therapeutics reports fourth quarter  financial results  pm march    globenewswire fate therapeutics announces fda clearance of investigational new drug application for fatenk natural killer cell cancer immunotherapy  am march    globenewswire fate therapeutics to webcast conference call reporting fourth quarter and full year  financial results  pm march    globenewswire fate therapeutics to highlight natural killer cell programs and engineered pluripotent cell platform for offtheshelf cancer immunotherapy at the  aacr annual meeting  pm march    globenewswire fate therapeutics to present at two upcoming conferences in march  pm march    globenewswire fate therapeutics and regents of the university of minnesota expand research collaboration for clinical translation of engineered ipscderived natural killer cell cancer immunotherapy  am feb    globenewswire fate therapeutics to present at the leerink partners th annual global healthcare conference  pm feb    globenewswire fate therapeutics announces first patient treated in protmunetm protect clinical trial for the prevention of graftversushost disease  am jan    globenewswire fate therapeutics announces private financing  am nov    globenewswire fate therapeutics reports third quarter  financial results  pm nov    globenewswire fate therapeutics announces oral presentation on natural killer cell product candidate fatenk at the  ash annual meeting  pm nov    globenewswire fate therapeutics to webcast conference call reporting third quarter  financial results on november    pm oct    globenewswire fate therapeutics announces issuance of us patent protecting enhanced hematopoietic stem cell compositions  am oct    globenewswire fate therapeutics receives fda orphan drug designation for protmunetm in allogeneic hematopoietic cell transplantation  am sept    globenewswire fate therapeutics and memorial sloan kettering cancer center launch partnership for development of offtheshelf tcell immunotherapies  am sept    globenewswire loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pall the companies in jeff bezos’s empire in one large chart pbaker hughes data show weekly us oilrig count up a third time this month pamazon’s postearnings stock selloff is the smallest in seven years peuropean stocks end at month low as ubs falls tech worries weigh psurging australian dollar makes life tough for central bankers pus weekly active oilrig count up  at  baker hughes pus total weekly active drillingrig count up  at  baker hughes pseptember wti oil trades at bbl little changed from before the rig data pwhy the sec’s crackdown could be good for initial coin offerings pmattel shares down  in friday trading pexpedia stock price target raised to  from  at ubs paarons shares up  in friday trading pwhere healthcare reform goes after failure to repeal and replace obamacare psp  down  points or  at  pdow industrials down  points at  pbreakingnasdaq pares losses down  points at  pftse  closes sharply lower in tobaccoled stock rout phere’s how much you should spend on a yoga mat and why you should always use your own phow advisers can fight the ‘crisis of trust’ in financial services phow venezuela chaos could spark oil rally opec has failed to achieve loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one fate therapeutics  torrey pines  san diego ca foursquarelog insign upnearbyget inspiredtop pickstrendingfoodcoffeenightlifefunshoppingplanning a trip to san diegofoursquare can help you find the best places to go tofind great things to dofate therapeuticsdoctors officetorrey pines san diegosavesharetipsfate therapeuticsno tips and reviewslog in to leave a tip herepostno tips yetwrite a short note about what you liked what to order or other helpful advice for visitors photorelated searchesfate therapeutics san diego  fate therapeutics san diego photos  fate therapeutics san diego location  fate therapeutics san diego address  fate therapeutics san diego  fate therapeutics san diego  fate therapeutics torrey pines san diegoaboutblogbusinessescitiesdevelopershelpjobscookies updatedprivacy updatedtermsenglishenglish français deutsch bahasa indonesia italiano  한국어 português русский español ภาษาไทย türkçe citiesatlantaaustinbostonchicagodallasdenverhoustonlas vegaslos angelesnew yorkphiladelphiaportlandsan diegosan franciscoseattlewashington dccountriesbelgiumbrazilcanadachilefinlandfrancegermanygreat britainhungaryindonesiajapanmexiconetherlandsphilippinesrussiasingaporespainthailandturkeyfoursquare    lovingly made in nyc  sffate therapeutics general atomics ct john jay hopkins drsan diego ca united statesget directions  fatetherapeuticsee moreis this your business claim it nowmake sure your information is up to date plus use our free tools to find new customersyou must enable javascript to use foursquarecomwe use the latest and greatest technology available to provide the best possible web experienceplease enable javascript in your browser settings to continuedownload foursquare for your smart phone and start exploring the world around you home  fate therapeutics for immunoregulation tcell nk cell for immunooncology cd fate therapeutics one cell many fates for immunooncology cd for immunoregulation tcell nk cell transforming the lives of patients with cancer and immune disorders fatenk engineered hncd ink engineered car it cell protmune™ toleracyte™ menu about us our mission our cells of interest management board of directors pipeline overview immunooncology candidates fatenk engineered hncdink engineered car it cell immunoregulation candidates protmune™ toleracyte™ science ex vivo cell modulation ipsc product platform isscr annual meeting and presentations isscr  annual meeting collaborations join our team career opportunities vision mission values working at fate investors overview press releases events  presentations financials  filings sec filings annual reports and proxies corporate governance stock information historical stock lookup investors faqs contact contact  fate therapeutics fate therapeutics contact fate therapeutics inc  general atomics court suite  san diego ca  coming from the north  south to genesee  exit right on genesee  right on john j hopkins dr  right on general atomics ct fate is the first building on the right coming from the south  north to genesee  exit left on genesee  right on john j hopkins dr  right on general atomics ct fate is the first building on the right general contact  local  tollfree infofatetherapeuticscom human resources careersfatetherapeuticscom business development bdfatetherapeuticscom menu about us our mission our cells of interest management board of directors pipeline overview immunooncology candidates fatenk engineered hncdink engineered car it cell immunoregulation candidates protmune™ toleracyte™ science ex vivo cell modulation ipsc product platform isscr annual meeting and presentations isscr  annual meeting collaborations join our team career opportunities vision mission values working at fate investors overview press releases events  presentations financials  filings sec filings annual reports and proxies corporate governance stock information historical stock lookup investors faqs contact legal  fate therapeutics fate therapeutics legal terms and conditions please review the following terms that govern your use of our website the “terms of use” your continued use of our website constitutes your agreement to follow and be bound by the terms of use these terms of use are effective as of october   as we continue to develop our website we may from time to time modify alter or update these terms of use your use of our website following any such change constitutes your agreement to follow and be bound by the terms of use as changed we therefore encourage you to refer to these terms of use on an ongoing basis scope of use unless otherwise noted the design of this website the website as a whole and all materials including images illustrations and designs that are part of the website collectively the “contents” are copyrights trademarks trade dress andor other intellectual properties owned controlled or licensed by fate “fate” and the fate logo are registered trademarks of fate therapeutics inc unauthorized use of any fate trademark or logo may be a violation of federal and state trademark laws this website also is protected by us and foreign copyright laws the contents of our website are intended solely for personal noncommercial use by the users of our website you may download or copy the contents displayed on our website for your personal noncommercial use only so long as your copy retains any copyright and trademark notices appearing on our website no right title or interest in any downloaded materials is transferred to you as a result of any such downloading or copying you may not reproduce except as noted above publish transmit distribute display modify create derivative works from sell or participate in any sale of or exploit in any way in whole or in part any of the contents or the website comments feedback and other submissions we welcome your comments and feedback regarding our website our products and our services we do not however accept confidential or proprietary information accordingly all comments feedback ideas suggestions disclosed submitted or offered to fate using this website or otherwise collectively “comments” are not confidential and will become and remain fate’s property the disclosure submission or offer of any comments constitutes an assignment to fate of all worldwide rights titles and interests and goodwill in the comments without payment of any compensation comments submitted by you must not violate any right of any third party and must not contain any libelous abusive obscene or otherwise unlawful material product and medical information all product candidates referred to on this website are experimental have not been approved by the us food and drug administration or any other regulatory agency and are not available for sale nothing contained on this website is intended as a promotion of any product candidate or recommendation for the use of any product candidate in a way which conflicts with the laws and regulations of the country in which you are located the medical information and other content provided on this website is intended for general educational purposes only and is not intended as a substitute for professional medical advice diagnosis or treatment disclaimers this website has been prepared solely for the purpose of providing you with certain basic information about us however we do not make any representations as to the completeness or accuracy of the information which may be contained on this website in particular you should be aware that this information may be incomplete may contain errors or may have become outofdate in addition please note that this website and all contents of the website are provided on an “as is” basis without warranties of any kind either express or implied including without limitation warranties of title or implied warranties of merchantability or fitness for a particular purpose the website may be unavailable from time to time due to mechanical technical software hardware or thirdparty vendor failures updating or construction fate cannot predict or control when such downtime may occur and cannot control the duration of such downtime as a result fate does not warrant that your use of this website will be uninterrupted or error free fate also does not represent or warrant that this website or its server are free of viruses or other harmful elements your use of this website is at your sole risk you assume full responsibility for all costs associated with all necessary servicing or repairs of any equipment that you use in connection with your use of our website fate shall not be liable for any damages of any kind related to your use of this website neither fate nor its related entities or its vendors or content providers shall be liable to any person or entity for any direct or indirect loss damage whether actual consequential punitive special or otherwise injury claim or liability of any kind or character whatsoever based upon or resulting from your use or inability to use this website or any information or materials provided on the website if you are dissatisfied with the website or with any of these terms of use your sole and exclusive remedy is to discontinue using the website you agree to indemnify defend and hold harmless fate its stockholders officers directors employees agents distributors vendors and related entities from and against any and all third party claims demands liabilities costs or expenses including reasonable attorneys’ fees resulting or arising out of your breach of any of these terms of use privacy statement see the privacy statement relating to the collection and use of your information links to other sites we may provide links to other websites for your convenience in locating useful information such websites are not under our control accordingly we expressly disclaim any responsibility for the privacy policies information collection practices content accuracy of information andor quality of such thirdparty websites including any products andor services provided by or advertised on such thirdparty websites we are providing these links to you only as a convenience and the inclusion of any link does not indicate or imply any endorsement by us with respect to any third party or any website you are responsible for complying with all terms and conditions governing the use of linked websites limitations of liability in the event of any problem with this website or any information or material contained herein you agree that your sole remedy is to cease using this website in no event shall fate or its subsidiaries affiliates directors officers employees consultants representatives agents or any party involved in creating or producing this website or any information or material contained herein be liable for any special indirect incidental consequential punitive or exemplary damages or any other damages whatsoever resulting from the use of this website or with the delay or inability to use this website or any information or materials contained herein or otherwise arising out of the use of this website whether under a theory of breach of contract tort strict liability negligence or otherwise even if such party has been advised of the possibility of such damages menu about us our mission our cells of interest management board of directors pipeline overview immunooncology candidates fatenk engineered hncdink engineered car it cell immunoregulation candidates protmune™ toleracyte™ science ex vivo cell modulation ipsc product platform isscr annual meeting and presentations isscr  annual meeting collaborations join our team career opportunities vision mission values working at fate investors overview press releases events  presentations financials  filings sec filings annual reports and proxies corporate governance stock information historical stock lookup investors faqs contact home  fate therapeutics for immunoregulation tcell nk cell for immunooncology cd fate therapeutics one cell many fates for immunooncology cd for immunoregulation tcell nk cell transforming the lives of patients with cancer and immune disorders fatenk engineered hncd ink engineered car it cell protmune™ toleracyte™ menu about us our mission our cells of interest management board of directors pipeline overview immunooncology candidates fatenk engineered hncdink engineered car it cell immunoregulation candidates protmune™ toleracyte™ science ex vivo cell modulation ipsc product platform isscr annual meeting and presentations isscr  annual meeting collaborations join our team career opportunities vision mission values working at fate investors overview press releases events  presentations financials  filings sec filings annual reports and proxies corporate governance stock information historical stock lookup investors faqs contact fate stock price  fate therapeutics inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers algn  mhk  expe  col  fls  gt  mo  sbux  latest newsall times eastern p updated all the companies in jeff bezos’s empire in one large chart p baker hughes data show weekly us oilrig count up a third time this month p amazon’s postearnings stock selloff is the smallest in seven years p updated european stocks end at month low as ubs falls tech worries weigh p surging australian dollar makes life tough for central bankers p september wti oil trades at bbl little changed from before the rig data p us total weekly active drillingrig count up  at  baker hughes p us weekly active oilrig count up  at  baker hughes p opinion why the sec’s crackdown could be good for initial coin offerings p mattel shares down  in friday trading to be replaced home investing quotes stocks united states fate overview compare quotes stock screener earnings calendar sectors nasdaq fate us nasdaq join td ameritrade find a broker fate therapeutics inc watchlist createfatealert open last updated jul    pm edt real time quote     previous close  advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  last   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones no headlines available no headlines available recent news other news press releases ecor capital llc buys cytomx therapeutics inc cascadian therapeutics inc fate therapeutics  ecor capital llc buys cytomx therapeutics inc cascadian therapeutics inc fate therapeutics inc sells alexion pharmaceuticals inc ardelyx inc five prime therapeutics inc may   at  pm et on gurufocuscom fate therapeutics fate ceo scott wolchko on q  results  earnings call transcript fate therapeutics fate ceo scott wolchko on q  results  earnings call transcript may   at  pm et on seeking alpha fda oks fate therapeutics ind for cancer candidate fatenk shares ahead  fda oks fate therapeutics ind for cancer candidate fatenk shares ahead  may   at  am et on seeking alpha q juno therapeutics inc q juno therapeutics inc may   at  pm et on edgar online  edg  q k surging earnings estimates signal good news for fate therapeutics fate mar   at  am et on zackscom biotech forum daily digest trump proposes changes at fda spotlight on quotient limited mar   at  am et on seeking alpha fate therapeutics fate ceo scott wolchko on q  results  earnings call transcript mar   at  pm et on seeking alpha k fate therapeutics inc mar   at  pm et on edgar online  edg  q k fate therapeutics cleared to begin clinical trial assessing nk cell therapy in blood cancer shares up  mar   at  am et on seeking alpha zackscom featured highlights apollo investment ballard power systems cymabay therapeutics fate therpautics and oclaro mar   at  am et on zackscom explosive stocks under  mar   at  pm et on zackscom  musthave biotechs for the next  months feb   at  pm et on seeking alpha fate therapeutics fate shares march higher can it continue feb   at  am et on zackscom forget alexion buy these  biotech stocks instead feb   at  am et on zackscom biotech focus near medium and longterm runners feb   at  pm et on seeking alpha the zacks analyst blog highlights gilead sciences celgene fate therapeutics exelixis and akebia therapeutics feb   at  am et on zackscom forget gilead buy these  biotech stocks instead feb   at  am et on zackscom fate therapeutics fate shares march higher can it continue jan   at  am et on zackscom fate therapeutics set to gain momentum in  jan   at  am et on seeking alpha biggest movers in manufacturing stocks now – txmd immu life wkhs dec   at  am et on investorplacecom fate therapeutics reports first quarter  financial results fate therapeutics reports first quarter  financial results may   at  pm et on globenewswire fate therapeutics announces fda clearance of investigational new drug application for fatenk in advanced solid tumors fate therapeutics announces fda clearance of investigational new drug application for fatenk in advanced solid tumors may   at  am et on globenewswire fate therapeutics to webcast conference call reporting first quarter  financial results fate therapeutics to webcast conference call reporting first quarter  financial results may   at  pm et on globenewswire fate therapeutics to kickoff  annual meeting of international society for stem cell research with offtheshelf natural killer cell cancer immunotherapy focus session apr   at  am et on globenewswire fate therapeutics to present at the th annual cell  gene therapy investor day apr   at  am et on globenewswire fate therapeutics reports fourth quarter  financial results mar   at  pm et on globenewswire fate therapeutics announces fda clearance of investigational new drug application for fatenk natural killer cell cancer immunotherapy mar   at  am et on globenewswire fate therapeutics to webcast conference call reporting fourth quarter and full year  financial results mar   at  pm et on globenewswire fate therapeutics to highlight natural killer cell programs and engineered pluripotent cell platform for offtheshelf cancer immunotherapy at the  aacr annual meeting mar   at  pm et on globenewswire fate therapeutics to present at two upcoming conferences in march mar   at  pm et on globenewswire fate therapeutics and regents of the university of minnesota expand research collaboration for clinical translation of engineered ipscderived natural killer cell cancer immunotherapy feb   at  am et on globenewswire fate therapeutics to present at the leerink partners th annual global healthcare conference feb   at  pm et on globenewswire fate therapeutics announces first patient treated in protmunetm protect clinical trial for the prevention of graftversushost disease jan   at  am et on globenewswire fate therapeutics announces private financing nov   at  am et on globenewswire fate therapeutics reports third quarter  financial results nov   at  pm et on globenewswire fate therapeutics announces oral presentation on natural killer cell product candidate fatenk at the  ash annual meeting nov   at  pm et on globenewswire fate therapeutics to webcast conference call reporting third quarter  financial results on november   oct   at  pm et on globenewswire fate therapeutics announces issuance of us patent protecting enhanced hematopoietic stem cell compositions oct   at  am et on globenewswire fate therapeutics receives fda orphan drug designation for protmunetm in allogeneic hematopoietic cell transplantation sep   at  am et on globenewswire fate therapeutics and memorial sloan kettering cancer center launch partnership for development of offtheshelf tcell immunotherapies sep   at  am et on globenewswire fate therapeutics inc fate therapeutics inc is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder it programmed cellular therapeutics for the treatment of life threatening diseases hematologic malignancies genetic disorders and diseases resulting from the dysregulation of the immune system the company products include prohema protmune adaptive nk ipscderived nk programmed cd and t cell therapy fate therapeutics was founded by philip beachy sheng ding rudolf jaenisch randall t moon michael rudnicki david scadden leonard zon alexander rives scott wolchko and john d mendlein on april   and is headquartered in san diego ca see full profile analyst ratings sell under hold over buy number of ratings  full ratings a datarich year has analysts accepting their fate therapeutics trade mar   at  am et on benzingacom benzingas top initiations sep   at  am et on benzingacom benzingas top initiations sep   at  am et on benzingacom competitors name chg  market cap neurocrine biosciences inc  b becton dickinson  co  b sarepta therapeutics inc  b ptc therapeutics inc  m ionis pharmaceuticals inc  b competitor data provided by partner content trending tickers powered by aks  x  dvax  sbux  bidu  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience fate stock price  fate therapeutics inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers algn  mhk  expe  col  fls  gt  sbux  mo  latest newsall times eastern p updated all the companies in jeff bezos’s empire in one large chart p baker hughes data show weekly us oilrig count up a third time this month p amazon’s postearnings stock selloff is the smallest in seven years p updated european stocks end at month low as ubs falls tech worries weigh p surging australian dollar makes life tough for central bankers p september wti oil trades at bbl little changed from before the rig data p us total weekly active drillingrig count up  at  baker hughes p us weekly active oilrig count up  at  baker hughes p opinion why the sec’s crackdown could be good for initial coin offerings p mattel shares down  in friday trading to be replaced home investing quotes stocks united states fate overview compare quotes stock screener earnings calendar sectors nasdaq fate us nasdaq join td ameritrade find a broker fate therapeutics inc watchlist createfatealert open last updated jul    pm edt real time quote     previous close  advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  last   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones no headlines available no headlines available recent news other news press releases ecor capital llc buys cytomx therapeutics inc cascadian therapeutics inc fate therapeutics  ecor capital llc buys cytomx therapeutics inc cascadian therapeutics inc fate therapeutics inc sells alexion pharmaceuticals inc ardelyx inc five prime therapeutics inc may   at  pm et on gurufocuscom fate therapeutics fate ceo scott wolchko on q  results  earnings call transcript fate therapeutics fate ceo scott wolchko on q  results  earnings call transcript may   at  pm et on seeking alpha fda oks fate therapeutics ind for cancer candidate fatenk shares ahead  fda oks fate therapeutics ind for cancer candidate fatenk shares ahead  may   at  am et on seeking alpha q juno therapeutics inc q juno therapeutics inc may   at  pm et on edgar online  edg  q k surging earnings estimates signal good news for fate therapeutics fate mar   at  am et on zackscom biotech forum daily digest trump proposes changes at fda spotlight on quotient limited mar   at  am et on seeking alpha fate therapeutics fate ceo scott wolchko on q  results  earnings call transcript mar   at  pm et on seeking alpha k fate therapeutics inc mar   at  pm et on edgar online  edg  q k fate therapeutics cleared to begin clinical trial assessing nk cell therapy in blood cancer shares up  mar   at  am et on seeking alpha zackscom featured highlights apollo investment ballard power systems cymabay therapeutics fate therpautics and oclaro mar   at  am et on zackscom explosive stocks under  mar   at  pm et on zackscom  musthave biotechs for the next  months feb   at  pm et on seeking alpha fate therapeutics fate shares march higher can it continue feb   at  am et on zackscom forget alexion buy these  biotech stocks instead feb   at  am et on zackscom biotech focus near medium and longterm runners feb   at  pm et on seeking alpha the zacks analyst blog highlights gilead sciences celgene fate therapeutics exelixis and akebia therapeutics feb   at  am et on zackscom forget gilead buy these  biotech stocks instead feb   at  am et on zackscom fate therapeutics fate shares march higher can it continue jan   at  am et on zackscom fate therapeutics set to gain momentum in  jan   at  am et on seeking alpha biggest movers in manufacturing stocks now – txmd immu life wkhs dec   at  am et on investorplacecom fate therapeutics reports first quarter  financial results fate therapeutics reports first quarter  financial results may   at  pm et on globenewswire fate therapeutics announces fda clearance of investigational new drug application for fatenk in advanced solid tumors fate therapeutics announces fda clearance of investigational new drug application for fatenk in advanced solid tumors may   at  am et on globenewswire fate therapeutics to webcast conference call reporting first quarter  financial results fate therapeutics to webcast conference call reporting first quarter  financial results may   at  pm et on globenewswire fate therapeutics to kickoff  annual meeting of international society for stem cell research with offtheshelf natural killer cell cancer immunotherapy focus session apr   at  am et on globenewswire fate therapeutics to present at the th annual cell  gene therapy investor day apr   at  am et on globenewswire fate therapeutics reports fourth quarter  financial results mar   at  pm et on globenewswire fate therapeutics announces fda clearance of investigational new drug application for fatenk natural killer cell cancer immunotherapy mar   at  am et on globenewswire fate therapeutics to webcast conference call reporting fourth quarter and full year  financial results mar   at  pm et on globenewswire fate therapeutics to highlight natural killer cell programs and engineered pluripotent cell platform for offtheshelf cancer immunotherapy at the  aacr annual meeting mar   at  pm et on globenewswire fate therapeutics to present at two upcoming conferences in march mar   at  pm et on globenewswire fate therapeutics and regents of the university of minnesota expand research collaboration for clinical translation of engineered ipscderived natural killer cell cancer immunotherapy feb   at  am et on globenewswire fate therapeutics to present at the leerink partners th annual global healthcare conference feb   at  pm et on globenewswire fate therapeutics announces first patient treated in protmunetm protect clinical trial for the prevention of graftversushost disease jan   at  am et on globenewswire fate therapeutics announces private financing nov   at  am et on globenewswire fate therapeutics reports third quarter  financial results nov   at  pm et on globenewswire fate therapeutics announces oral presentation on natural killer cell product candidate fatenk at the  ash annual meeting nov   at  pm et on globenewswire fate therapeutics to webcast conference call reporting third quarter  financial results on november   oct   at  pm et on globenewswire fate therapeutics announces issuance of us patent protecting enhanced hematopoietic stem cell compositions oct   at  am et on globenewswire fate therapeutics receives fda orphan drug designation for protmunetm in allogeneic hematopoietic cell transplantation sep   at  am et on globenewswire fate therapeutics and memorial sloan kettering cancer center launch partnership for development of offtheshelf tcell immunotherapies sep   at  am et on globenewswire fate therapeutics inc fate therapeutics inc is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder it programmed cellular therapeutics for the treatment of life threatening diseases hematologic malignancies genetic disorders and diseases resulting from the dysregulation of the immune system the company products include prohema protmune adaptive nk ipscderived nk programmed cd and t cell therapy fate therapeutics was founded by philip beachy sheng ding rudolf jaenisch randall t moon michael rudnicki david scadden leonard zon alexander rives scott wolchko and john d mendlein on april   and is headquartered in san diego ca see full profile analyst ratings sell under hold over buy number of ratings  full ratings a datarich year has analysts accepting their fate therapeutics trade mar   at  am et on benzingacom benzingas top initiations sep   at  am et on benzingacom benzingas top initiations sep   at  am et on benzingacom competitors name chg  market cap neurocrine biosciences inc  b becton dickinson  co  b sarepta therapeutics inc  b ptc therapeutics inc  m ionis pharmaceuticals inc  b competitor data provided by partner content trending tickers powered by aks  x  dvax  sbux  bidu  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience fate therapeutics inc  product pipeline review   market segments size trend and market projections for upcoming years salesmarketresearchreportsbiz      home pharmaceuticals and healthcare pharmaceutical fate therapeutics inc  product pipeline review   fate therapeutics inc  product pipeline review    pages global markets direct   in stock description table of contents related reports request sample fate therapeutics inc  product pipeline review  summaryglobal markets directs fate therapeutics inc  product pipeline review   provides an overview of the fate therapeutics incs pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of fate therapeutics incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of fate therapeutics inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of fate therapeutics incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the fate therapeutics incs pipeline productsreasons to buy evaluate fate therapeutics incs strategic position with total access to detailed information on its product pipeline assess the growth potential of fate therapeutics inc in its therapy areas of focus identify new drug targets and therapeutic classes in the fate therapeutics incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of fate therapeutics inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of fate therapeutics inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of fate therapeutics inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures fate therapeutics inc snapshot fate therapeutics inc overview key information key facts fate therapeutics inc  research and development overview key therapeutic areas fate therapeutics inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities fate therapeutics inc  pipeline products glance fate therapeutics inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities fate therapeutics inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities fate therapeutics inc  drug profiles ft product description mechanism of action rd progress cell therapy for solid tumors and blood cancer product description mechanism of action rd progress protmune product description mechanism of action rd progress stem cell therapy  for undisclosed indication product description mechanism of action rd progress stem cell therapy for hearing disorders product description mechanism of action rd progress stem cell therapy for inflammation and autoimmune diseases product description mechanism of action rd progress stem cell therapy for lysosomal storage disorder product description mechanism of action rd progress stem cell therapy for musculoskeletal disorders product description mechanism of action rd progress stem cell therapy  for undisclosed indication product description mechanism of action rd progress stem cell therapy for solid tumors and blood cancer product description mechanism of action rd progress fate therapeutics inc  pipeline analysis fate therapeutics inc  pipeline products by molecule type fate therapeutics inc  recent pipeline updates fate therapeutics inc  dormant projects fate therapeutics inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesfate therapeutics inc key information fate therapeutics inc key facts fate therapeutics inc  pipeline by indication  fate therapeutics inc  pipeline by stage of development  fate therapeutics inc  monotherapy products in pipeline  fate therapeutics inc  partnered products in pipeline  fate therapeutics inc  partnered products combination treatment modalities  fate therapeutics inc  phase ii  fate therapeutics inc  phase i  fate therapeutics inc  preclinical  fate therapeutics inc  discovery  fate therapeutics inc  pipeline by molecule type  fate therapeutics inc  recent pipeline updates  fate therapeutics inc  dormant developmental projects list of figuresfate therapeutics inc  pipeline by top  indication  fate therapeutics inc  pipeline by stage of development  fate therapeutics inc  monotherapy products in pipeline  fate therapeutics inc  pipeline by top  molecule type   related reports global hard gelatin capsules market professional survey report  this report studies hard gelatin capsules in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to this report focuses on top manufacturers in glob global dental cements market professional survey report  this report studies dental cements in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to this report focuses on top manufacturers in global mark asiapacific zinc oral drops market report  in this report the asiapacific zinc oral drops market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and geographically this report split asiapacific into several key regions with sales k units revenu asiapacific zinc gluconate supplement market report  in this report the asiapacific zinc gluconate supplement market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and geographically this report split asiapacific into several key regions with sales k unit asiapacific zinc drops market report  in this report the asiapacific zinc drops market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and geographically this report split asiapacific into several key regions with sales k units revenue mi related news why pain management therapeutics is behind the drug addiction problem in america alnylam reviews impact of fitusiran on hemophilia patients cord blood banking a lifeline for future generations global animal healthcare market thrives on growing incidences of animalrelated diseases sierra leone renews ebola alert view sample pdf purchase this market research report single license   multiple license   buy now download report pdf save page send an enquiry check discount request quote enquiry before buy popular reports global womens health diagnostics market size status and forecast  this report studies the global womens health diagnostics market analyzes and researches the womens health diagnostics development status and forecast in united states eu japan china india and southeast asia this report focuses on the top players in global market like siemens healthineers global venous thromboembolism therapeutics market size status and forecast  this report studies the global venous thromboembolism therapeutics market analyzes and researches the venous thromboembolism therapeutics development status and forecast in united states eu japan china india and southeast asia this report focuses on the top players in global market like jo global factor ix deficiency treatment market size status and forecast  this report studies the global factor ix deficiency treatment market analyzes and researches the factor ix deficiency treatment development status and forecast in united states eu japan china india and southeast asia this report focuses on the top players in global market like pfizer sh global directtoconsumer genetic testing market size status and forecast  this report studies the global directtoconsumer genetic testing market analyzes and researches the directtoconsumer genetic testing development status and forecast in united states eu japan china india and southeast asia this report focuses on the top players in global market like an global critical care therapeutics market size status and forecast  this report studies the global critical care therapeutics market analyzes and researches the critical care therapeutics development status and forecast in united states eu japan china india and southeast asia this report focuses on the top players in global market like csl behring shire microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft market report fate therapeutics inc  product pipeline review   about us • publishers • contact us • cart login  register all industries business  finance  business  financial services  insurance  marketing consumer  food  beverages  consumer goods  food  retailing healthcare  biotechnology  healthcare  medical devices  pharmaceuticals heavy industry  construction  energy  manufacturing  materials  transportation internet  media  ebusiness  internet  media  publishing public sector  defense  education  government telecom  computing  computer technology  fixed networks  software  wireless companycountry reports  company reports  country reports  regional reports   processing fate therapeutics inc  product pipeline review   may    global markets direct   pages  usd  click here to open the popup youve added the following report to your cartclose cart summary total items subtotal      report summary table of contents request details related global markets directs fate therapeutics inc  product pipeline review   provides an overview of the fate therapeutics incs pharmaceutical research and development focusthe report provides comprehensive information on the therapeutics under development by fate therapeutics inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basisthe report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantagenote certain sections in the report may be removed or altered based on the availability and relevance of datareport scopethe report provides a snapshot of the pipeline therapeutic landscape of fate therapeutics incthe report provides overview of fate therapeutics inc including its business description key facts and locations and subsidiariesthe report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activitiesthe report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stagesthe report assesses fate therapeutics incs pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule typethe report features fate therapeutics incs outlicensed and partnered product portfolio and summarizes its dormant and discontinued projectsreasons to get this reportevaluate fate therapeutics incs strategic position with total access to detailed information on its product pipelinegain strategically significant competitor information analysis and insights to formulate effective rd strategiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageidentify and understand important and diverse types of therapeutics under development for fate therapeutics incidentify potential new clients or partners in the target demographicplan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeuticsdevise corrective measures for pipeline projects by understanding fate therapeutics incs pipeline depth and focus of pipeline therapeuticsdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contentstable of contents list of tables list of figures report guidance clinical trials by region clinical trials and average enrollment by country top five countries contributing to clinical trials in asiapacific top five countries contributing to clinical trials in europe top countries contributing to clinical trials in north america top countries contributing to clinical trials in middle east and africa clinical trials by g countries proportion of vascular dementias to central nervous system clinical trials clinical trials by phase in g countries clinical trials in g countries by trial status clinical trials by e countries proportion of vascular dementias to central nervous system clinical trials clinical trials by phase in e countries clinical trials in e countries by trial status clinical trials by phase in progress trials by phase clinical trials by trial status clinical trials by end point status subjects recruited over a period of time clinical trials by sponsor type prominent sponsors top companies participating in vascular dementias therapeutics clinical trials prominent drugs clinical trial profile snapshots appendix abbreviations definitions research methodology secondary research about globaldata contact us disclaimer source list of tablesfate therapeutics inc key information fate therapeutics inc key facts fate therapeutics inc  pipeline by indication  fate therapeutics inc  pipeline by stage of development  fate therapeutics inc  monotherapy products in pipeline  fate therapeutics inc  partnered products in pipeline  fate therapeutics inc  partnered products combination treatment modalities  fate therapeutics inc  indcta filed  fate therapeutics inc  preclinical  fate therapeutics inc  discovery  fate therapeutics inc  pipeline by molecule type  fate therapeutics inc  recent pipeline updates  fate therapeutics inc  dormant developmental projects fate therapeutics inc  discontinued pipeline products  fate therapeutics inc subsidiaries list of figuresfate therapeutics inc  pipeline by top  indication  fate therapeutics inc  pipeline by stage of development  fate therapeutics inc  monotherapy products in pipeline  fate therapeutics inc  pipeline by molecule type   this report does not have a list of companies mentioned available this report does not have a press release associated with it order today format pdf  usd license single user delivery by email   business day the fast market research advantage only the best all of our research is sourced from the most trusted and established global analysts and consultancies client focused from startups to multinationals we focus on providing the right research to our diverse client base shop securely our usbased customer service team and ecommerce systems adhere to the highest data security standards industryleading customer support individualized assistance from our expert staff is never more than an email or phone call away best price guarantee we are committed to providing the best research at the lowest cost we will match any published price for the same report guaranteed easy ordering once you’ve found the right report click ‘order now’ and complete the checkout process using any major credit card check or wirebank transferneed multiuser or enterprise license pricing contact us for a custom quote about the publisher global markets direct is a leading provider of global business intelligence and market analysis it publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industryspecific information publisher details privacy policy  terms of use  flashalerts copyright copy  fast market research inc press releases  fate therapeutics inc fate therapeutics press releases filter releases year all years          sort by date descending date ascending update   press releases date title and summary view may   fate therapeutics reports first quarter  financial results protmune™ protect safety data expected in mid launched firstinhuman clinical trial of fatenk for acute myelogenous leukemia ind cleared by fda for fatenk with monoclonal antibody therapy in advanced solid tumors  read all » html pdf add to briefcase file is in briefcase may   fate therapeutics announces fda clearance of investigational new drug application for fatenk in advanced solid tumors san diego may   globe newswire  fate therapeutics inc nasdaqfate a clinicalstage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that the us food and drug administration fda has authorized the companys investiga read all » html pdf add to briefcase file is in briefcase may   fate therapeutics to webcast conference call reporting first quarter  financial results san diego may   globe newswire  fate therapeutics inc nasdaqfate a clinicalstage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that the company will host a conference call and live audio webcast on monday may   read all » html pdf add to briefcase file is in briefcase apr   fate therapeutics to kickoff  annual meeting of international society for stem cell research with offtheshelf natural killer cell cancer immunotherapy focus session san diego april   globe newswire  fate therapeutics inc nasdaqfate a clinicalstage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders today announced that it will host a focus session entitled offtheshelf natural killer cell cancer  read all » html pdf add to briefcase file is in briefcase apr   fate therapeutics to present at the th annual cell  gene therapy investor day san diego april   globe newswire  fate therapeutics inc nasdaqfate a clinicalstage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders today announced that scott wolchko president and chief executive officer will present at the  read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics reports fourth quarter  financial results first subject treated with protmune™ for gvhd prevention ind cleared by fda for fatenk natural killer cell product candidate in aml firstofkind cancer immunotherapy derived from engineered pluripotent cell line to begin clinical translation read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics announces fda clearance of investigational new drug application for fatenk natural killer cell cancer immunotherapy san diego march   globe newswire  fate therapeutics inc nasdaqfate a clinicalstage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that the us food and drug administration fda has cleared an investigational ne read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics to webcast conference call reporting fourth quarter and full year  financial results san diego march   globe newswire  fate therapeutics inc nasdaqfate a clinicalstage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that the company will host a conference call and live audio webcast on thursday marc read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics to highlight natural killer cell programs and engineered pluripotent cell platform for offtheshelf cancer immunotherapy at the  aacr annual meeting san diego march   globe newswire  fate therapeutics inc nasdaqfate a clinicalstage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that three abstracts describing the companys programs will be presented at the upcom read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics to present at two upcoming conferences in march san diego march   globe newswire  fate therapeutics inc nasdaqfate a clinicalstage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders today announced that it will present at two conferences in march the presentations will feature a  read all » html pdf add to briefcase file is in briefcase feb   fate therapeutics and regents of the university of minnesota expand research collaboration for clinical translation of engineered ipscderived natural killer cell cancer immunotherapy offtheshelf natural killer cell therapy being developed to complement standardofcare monoclonal antibody treatment for cancer firstofkind product candidate to be manufactured from an engineered induced pluripotent stem cell line intellectual property read all » html pdf add to briefcase file is in briefcase feb   fate therapeutics to present at the leerink partners th annual global healthcare conference san diego feb   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that scott wolchko president and chief executive officer will present at the leerink partners  read all » html pdf add to briefcase file is in briefcase jan   fate therapeutics announces first patient treated in protmune™ protect clinical trial for the prevention of graftversushost disease san diego jan   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that the first patient has been treated in its protect clinical trial of protmune for the prevention of read all » html pdf add to briefcase file is in briefcase nov   fate therapeutics announces private financing san diego nov   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders today announced that it has entered into a definitive securities purchase agreement with certain institutional and ot read all » html pdf add to briefcase file is in briefcase nov   fate therapeutics reports third quarter  financial results ind filed for fatenk adaptive natural killer cell immunotherapy in acute myeloid leukemia orphan drug designations for protmune granted by fda and ema protmune™ protect clinical protocol amended to facilitate path for accelerated registr read all » html pdf add to briefcase file is in briefcase page     next last   view all items  add release to briefcase facebook google linkedin twitter email rss menu about us our focus management board of directors pipeline overview immunooncology candidates fatenk engineered hncdink engineered car it cell immunoregulation candidates protmuneâ„¢ toleracyteâ„¢ science cell programming science programming cell function programming cell fate ipscs isscr annual meeting collaborations join our team career opportunities vision mission values working at fate investors overview press releases events  presentations financials  filings sec filings annual reports and proxies corporate governance stock information historical stock lookup investors faqs contact working at fate  fate therapeutics fate therapeutics working at fate fate therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders we believe better cell therapies start with better cells combining our deep understanding of hematopoietic cell biology with an unmatched expertise in programming cell function and fate we are creating disruptive cellular immunotherapies with transformative biological properties and profound therapeutic potential join fate and you will be a part of an intensely passionate imaginative and talented team we recognize that our success as a company depends on the innovation drive and dedication of our team and we seek to attract incentivize and reward creative and performancedriven employees ultimately you will create your own path as we support career development opportunities for all of our employees fate has an open collaborative and entrepreneurial environment where crossfunctional innovators and problemsolvers shine to acknowledge and support your commitment we offer competitive pay with performancebased bonuses and stock option awards and a comprehensive benefits program offering flexibility to meet your individual needs and requirements our program includes a choice of healthcare plans vision and dental coverage income protection through life add and longterm disability coverage paid family leave a k plan and generous paid time off to foster your health and wellbeing we maintain a stateofthe art fitness center onsite at no cost to employees and offer an employee assistance program fate is located in newly renovated offices in the heart of the biotech cluster atop beautiful torrey mesa in san diego california if this sounds like the kind of work and intellectual environment that energizes you we encourage you to reach out to us to find out more about fate we can be contacted at careersfatetherapeuticscom fate is an equal opportunity employer that offers competitive salary and benefits including equity participation menu about us our mission our cells of interest management board of directors pipeline overview immunooncology candidates fatenk engineered hncdink engineered car it cell immunoregulation candidates protmune™ toleracyte™ science ex vivo cell modulation ipsc product platform isscr annual meeting and presentations isscr  annual meeting collaborations join our team career opportunities vision mission values working at fate investors overview press releases events  presentations financials  filings sec filings annual reports and proxies corporate governance stock information historical stock lookup investors faqs contact fate therapeutics inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports fate therapeutics inc  product pipeline review   fate therapeutics inc  product pipeline review   wgr  may  global  pages global markets direct description table of content sample report enquiry before buy related reports fate therapeutics inc  product pipeline review   summary global markets direct’s ‘fate therapeutics inc  product pipeline review  ’ provides an overview of the fate therapeutics inc’s pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by fate therapeutics inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis the report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage note certain sections in the report may be removed or altered based on the availability and relevance of data scope  the report provides a snapshot of the pipeline therapeutic landscape of fate therapeutics inc  the report provides overview of fate therapeutics inc including its business description key facts and locations and subsidiaries  the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities  the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages  the report assesses fate therapeutics inc’s pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type  the report features fate therapeutics inc’s outlicensed and partnered product portfolio and summarizes its dormant and discontinued projects reasons to buy  evaluate fate therapeutics inc’s strategic position with total access to detailed information on its product pipeline  gain strategically significant competitor information analysis and insights to formulate effective rd strategies  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  identify and understand important and diverse types of therapeutics under development for fate therapeutics inc  identify potential new clients or partners in the target demographic  plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics  devise corrective measures for pipeline projects by understanding fate therapeutics inc’s pipeline depth and focus of pipeline therapeutics  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contents table of contents  list of tables  list of figures  fate therapeutics inc snapshot  fate therapeutics inc overview  key information  key facts  fate therapeutics inc  research and development overview  key therapeutic areas  fate therapeutics inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  partnered products  partnered productscombination treatment modalities  fate therapeutics inc  pipeline products glance  fate therapeutics inc  early stage pipeline products  indcta filed productscombination treatment modalities  preclinical productscombination treatment modalities  discovery productscombination treatment modalities  fate therapeutics inc  drug profiles  protmune  product description  mechanism of action  rd progress  cellular immunotherapy for solid tumors and hematological tumors  product description  mechanism of action  rd progress  stem cell therapy  for undisclosed indication  product description  mechanism of action  rd progress  stem cell therapy for hearing disorders  product description  mechanism of action  rd progress  stem cell therapy for hematological and solid tumors  product description  mechanism of action  rd progress  stem cell therapy for inflammation and autoimmune diseases  product description  mechanism of action  rd progress  stem cell therapy for lysosomal storage disorder  product description  mechanism of action  rd progress  stem cell therapy for solid tumors and hematologic malignancies  product description  mechanism of action  rd progress  stem cell therapy for musculoskeletal disorders  product description  mechanism of action  rd progress  stem cell therapy  for undisclosed indication  product description  mechanism of action  rd progress  fate therapeutics inc  pipeline analysis  fate therapeutics inc  pipeline products by molecule type  fate therapeutics inc  recent pipeline updates  fate therapeutics inc  dormant projects  fate therapeutics inc  discontinued pipeline products  discontinued pipeline product profiles  ft  fate therapeutics inc  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables fate therapeutics inc key information  fate therapeutics inc key facts  fate therapeutics inc  pipeline by indication   fate therapeutics inc  pipeline by stage of development   fate therapeutics inc  monotherapy products in pipeline   fate therapeutics inc  partnered products in pipeline   fate therapeutics inc  partnered products combination treatment modalities   fate therapeutics inc  indcta filed   fate therapeutics inc  preclinical   fate therapeutics inc  discovery   fate therapeutics inc  pipeline by molecule type   fate therapeutics inc  recent pipeline updates   fate therapeutics inc  dormant developmental projects  fate therapeutics inc  discontinued pipeline products   fate therapeutics inc subsidiaries  list of figures fate therapeutics inc  pipeline by top  indication   fate therapeutics inc  pipeline by stage of development   fate therapeutics inc  monotherapy products in pipeline   fate therapeutics inc  pipeline by molecule type   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     pipeline  fate therapeutics fate therapeutics pipeline immunooncology preclinical clinical rights fatenk – aml worldwide fatenk – solid tumor mab combo worldwide fatenk – ovarian worldwide engineered hncd ink worldwide engineered car it cell worldwide ex vivo tcell modulation collaboration milestone  royalties immunoregulation protmune™ – graftversushost disease worldwide toleracyte™ – autoimmune disorders worldwide engineered ireg cell worldwide immunooncology phase rights fatenk – aml clinical worldwide fatenk – solid tumor mab combo clinical worldwide fatenk – ovarian preclinical worldwide engineered hncd ink preclinical worldwide engineered car it cell preclinical worldwide ex vivo tcell modulation collaboration preclinical milestone  royalties immunoregulation protmune™ – graftversushost disease clinical worldwide toleracyte™ – autoimmune disorders preclinical worldwide engineered ireg cell preclinical worldwide our cell therapy product pipeline is comprised of firstinclass cellular immunotherapies for cancer and immune disorders our programs reflect our dedication and commitment to pioneering ground breaking science to address severe lifethreatening diseases where the unmet need is significant and the treatment options are limited menu about us our mission our cells of interest management board of directors pipeline overview immunooncology candidates fatenk engineered hncdink engineered car it cell immunoregulation candidates protmune™ toleracyte™ science ex vivo cell modulation ipsc product platform isscr annual meeting and presentations isscr  annual meeting collaborations join our team career opportunities vision mission values working at fate investors overview press releases events  presentations financials  filings sec filings annual reports and proxies corporate governance stock information historical stock lookup investors faqs contact fate therapeutics inc  product pipeline review    market research reports® inc skip to main content home faqs contact us become publisher blog  items  search form search this site search you are here home catalog pharma  healthcare company reports pharma  healthcare fate therapeutics inc  product pipeline review   fate therapeutics inc  product pipeline review   printer versionsend by email publication id gmd publication date  may   pages   publisher global markets direct countries  global  publication type   select single user license pdf site license pdf global license pdf  please choose the suitable license type from above more details are at given under tab report license types below add to cart why to buy from us globally trusted brand we help executives from fortune  firms to startups with their market research needs thus we can help you too  shop with confidence if you have any presales questions related to this report pelase let us know using the report enquiry form below this will help us provide you with answers so that you can purchase with confidence secure checkout you can shop confidently as your online payments are processed using pci dss compliant secure payment gateways on our website frequently asked questions if you wish to read about frequently asked questions by our customers please visit our faqs page tabsdescription fate therapeutics inc  product pipeline review   summary global markets direct’s ‘fate therapeutics inc  product pipeline review  ’ provides an overview of the fate therapeutics inc’s pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by fate therapeutics inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis the report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage note certain sections in the report may be removed or altered based on the availability and relevance of data scope  the report provides a snapshot of the pipeline therapeutic landscape of fate therapeutics inc  the report provides overview of fate therapeutics inc including its business description key facts and locations and subsidiaries  the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities  the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages  the report assesses fate therapeutics inc’s pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type  the report features fate therapeutics inc’s outlicensed and partnered product portfolio and summarizes its dormant and discontinued projects reasons to buy  evaluate fate therapeutics inc’s strategic position with total access to detailed information on its product pipeline  gain strategically significant competitor information analysis and insights to formulate effective rd strategies  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  identify and understand important and diverse types of therapeutics under development for fate therapeutics inc  identify potential new clients or partners in the target demographic  plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics  devise corrective measures for pipeline projects by understanding fate therapeutics inc’s pipeline depth and focus of pipeline therapeutics  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contents table of contents table of contents  list of tables  list of figures  fate therapeutics inc snapshot  fate therapeutics inc overview  key information  key facts  fate therapeutics inc  research and development overview  key therapeutic areas  fate therapeutics inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  partnered products  partnered productscombination treatment modalities  fate therapeutics inc  pipeline products glance  fate therapeutics inc  early stage pipeline products  indcta filed productscombination treatment modalities  preclinical productscombination treatment modalities  discovery productscombination treatment modalities  fate therapeutics inc  drug profiles  protmune  product description  mechanism of action  rd progress  cellular immunotherapy for solid tumors and hematological tumors  product description  mechanism of action  rd progress  stem cell therapy  for undisclosed indication  product description  mechanism of action  rd progress  stem cell therapy for hearing disorders  product description  mechanism of action  rd progress  stem cell therapy for hematological and solid tumors  product description  mechanism of action  rd progress  stem cell therapy for inflammation and autoimmune diseases  product description  mechanism of action  rd progress  stem cell therapy for lysosomal storage disorder  product description  mechanism of action  rd progress  stem cell therapy for solid tumors and hematologic malignancies  product description  mechanism of action  rd progress  stem cell therapy for musculoskeletal disorders  product description  mechanism of action  rd progress  stem cell therapy  for undisclosed indication  product description  mechanism of action  rd progress  fate therapeutics inc  pipeline analysis  fate therapeutics inc  pipeline products by molecule type  fate therapeutics inc  recent pipeline updates  fate therapeutics inc  dormant projects  fate therapeutics inc  discontinued pipeline products  discontinued pipeline product profiles  ft  fate therapeutics inc  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables fate therapeutics inc key information  fate therapeutics inc key facts  fate therapeutics inc  pipeline by indication   fate therapeutics inc  pipeline by stage of development   fate therapeutics inc  monotherapy products in pipeline   fate therapeutics inc  partnered products in pipeline   fate therapeutics inc  partnered products combination treatment modalities   fate therapeutics inc  indcta filed   fate therapeutics inc  preclinical   fate therapeutics inc  discovery   fate therapeutics inc  pipeline by molecule type   fate therapeutics inc  recent pipeline updates   fate therapeutics inc  dormant developmental projects  fate therapeutics inc  discontinued pipeline products   fate therapeutics inc subsidiaries  list of figures fate therapeutics inc  pipeline by top  indication   fate therapeutics inc  pipeline by stage of development   fate therapeutics inc  monotherapy products in pipeline   fate therapeutics inc  pipeline by molecule type   companies covered na report license types single user license pdf this license allows for use of a publication by one person this person may print out a single copy of the publication this person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher this person cannot share the publication or any information contained therein with any other person or persons unless a global license is purchased a single user license must be purchased for every person that wishes to use the publication within the same organization customers who infringe these license terms are liable for a global license fee   site license pdf this license allows for use of a publication by all users within one corporate location eg a regional office these users may print out a single copy of the publication these users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher these users cannot share the publication or any information contained therein with any other person or persons outside the corporate location for which the publication is purchased unless a global license is purchased a site user license must be purchased for every corporate location by an organization that wishes to use the publication within the same organization customers who infringe these license terms are liable for a global license fee   global license pdf this license allows for use of a publication by unlimited users within the purchasing organization eg all employees of a single company each of these people may use the publication on any computer and may print out the report but may not share the publication or any information contained therein with any other person or persons outside of the organization these employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher if applicable report enquiry do you have more questions related to this market research report after going through the description and table of contents we are here to help please use the form given below to let us know your questions related to this report kindly use your official email address and contact number to ensure speedy response first name  last name  company  email address  phone including international code  report title  your inquiry  captchathis question is for testing whether you are a human visitor and to prevent automated spam submissions math question      solve this simple math problem and enter the result eg for  enter  submit company reports pharma  healthcarepharma  healthcare please note that the report cover image shown above is for representation purpose only actual report cover may vary  single user license pdf market research reports® inc httpwwwmarketresearchreportscom related market research reports publication price bonesupport ab  medical equipment  deals and alliances profile summary  pulmonx corp  medical equipment  deals and alliances profile summary  hologic inc holx  medical equipment  deals and alliances profile summary  biosensors international group ltd  medical equipment  deals and alliances profile summary  bioreference laboratories inc  medical equipment  deals and alliances profile summary  siemens healthcare gmbh  medical equipment  deals and alliances profile summary  bioclinica inc  medical equipment  deals and alliances profile summary  invacare corporation ivc  medical equipment  deals and alliances profile summary  beckman coulter inc  medical equipment  deals and alliances profile summary  biolase inc biol  medical equipment  deals and alliances profile summary  cormatrix cardiovascular inc  medical equipment  deals and alliances profile summary  integra lifesciences holdings corp iart  medical equipment  deals and alliances profile summary  clients who trust us need tailor made market research solution we can help you with that too contact us about us at market research reports inc we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best ie take timecritical decisions we work with our associate global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer’s needs be it custom research or syndicated research reports contact us market research reports inc  coastal hwy lewes de  usa usa  india  marketresearchreports email protected user login username  password  create new account request new password log in latest blog posts investment opportunities in taiwan semiconductor chemical and consumer goods will lead the pack global investment opportunities in ports and terminals stay connected sign up to our newsletter email address  subscribe research industries home automotive banking  finance business  government chemicals computing  electronics consumer  retail energy  utilities food  beverages industry  manufacturing marketing  advertising media pharma  healthcare telecom transport travel  leisure our company about us publications by country faqs privacy policy terms  conditions  copyright  market research reports inc all rights reserved m market research reports and the m market research reports logo are registered trademarks of market research reports inc disclaimer market research reports inc has no affiliation to and is not associated with any other websites or organizations we offer syndicated research reports like country analysis swot analysis competitive intelligence industry reports company reports and market analysis  trends reports and custom market research from our website marketresearchreportscom only if you are looking for a market research solution for your research requirements please begin your search using the search box on top of this page or use our chat system to speak to our market research consultants or directly write to us press releases  fate therapeutics inc fate therapeutics press releases filter releases year all years          sort by date descending date ascending update   press releases date title and summary view may   fate therapeutics reports first quarter  financial results protmune™ protect safety data expected in mid launched firstinhuman clinical trial of fatenk for acute myelogenous leukemia ind cleared by fda for fatenk with monoclonal antibody therapy in advanced solid tumors  read all » html pdf add to briefcase file is in briefcase may   fate therapeutics announces fda clearance of investigational new drug application for fatenk in advanced solid tumors san diego may   globe newswire  fate therapeutics inc nasdaqfate a clinicalstage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that the us food and drug administration fda has authorized the companys investiga read all » html pdf add to briefcase file is in briefcase may   fate therapeutics to webcast conference call reporting first quarter  financial results san diego may   globe newswire  fate therapeutics inc nasdaqfate a clinicalstage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that the company will host a conference call and live audio webcast on monday may   read all » html pdf add to briefcase file is in briefcase apr   fate therapeutics to kickoff  annual meeting of international society for stem cell research with offtheshelf natural killer cell cancer immunotherapy focus session san diego april   globe newswire  fate therapeutics inc nasdaqfate a clinicalstage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders today announced that it will host a focus session entitled offtheshelf natural killer cell cancer  read all » html pdf add to briefcase file is in briefcase apr   fate therapeutics to present at the th annual cell  gene therapy investor day san diego april   globe newswire  fate therapeutics inc nasdaqfate a clinicalstage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders today announced that scott wolchko president and chief executive officer will present at the  read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics reports fourth quarter  financial results first subject treated with protmune™ for gvhd prevention ind cleared by fda for fatenk natural killer cell product candidate in aml firstofkind cancer immunotherapy derived from engineered pluripotent cell line to begin clinical translation read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics announces fda clearance of investigational new drug application for fatenk natural killer cell cancer immunotherapy san diego march   globe newswire  fate therapeutics inc nasdaqfate a clinicalstage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that the us food and drug administration fda has cleared an investigational ne read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics to webcast conference call reporting fourth quarter and full year  financial results san diego march   globe newswire  fate therapeutics inc nasdaqfate a clinicalstage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that the company will host a conference call and live audio webcast on thursday marc read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics to highlight natural killer cell programs and engineered pluripotent cell platform for offtheshelf cancer immunotherapy at the  aacr annual meeting san diego march   globe newswire  fate therapeutics inc nasdaqfate a clinicalstage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that three abstracts describing the companys programs will be presented at the upcom read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics to present at two upcoming conferences in march san diego march   globe newswire  fate therapeutics inc nasdaqfate a clinicalstage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders today announced that it will present at two conferences in march the presentations will feature a  read all » html pdf add to briefcase file is in briefcase feb   fate therapeutics and regents of the university of minnesota expand research collaboration for clinical translation of engineered ipscderived natural killer cell cancer immunotherapy offtheshelf natural killer cell therapy being developed to complement standardofcare monoclonal antibody treatment for cancer firstofkind product candidate to be manufactured from an engineered induced pluripotent stem cell line intellectual property read all » html pdf add to briefcase file is in briefcase feb   fate therapeutics to present at the leerink partners th annual global healthcare conference san diego feb   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that scott wolchko president and chief executive officer will present at the leerink partners  read all » html pdf add to briefcase file is in briefcase jan   fate therapeutics announces first patient treated in protmune™ protect clinical trial for the prevention of graftversushost disease san diego jan   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that the first patient has been treated in its protect clinical trial of protmune for the prevention of read all » html pdf add to briefcase file is in briefcase nov   fate therapeutics announces private financing san diego nov   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders today announced that it has entered into a definitive securities purchase agreement with certain institutional and ot read all » html pdf add to briefcase file is in briefcase nov   fate therapeutics reports third quarter  financial results ind filed for fatenk adaptive natural killer cell immunotherapy in acute myeloid leukemia orphan drug designations for protmune granted by fda and ema protmune™ protect clinical protocol amended to facilitate path for accelerated registr read all » html pdf add to briefcase file is in briefcase nov   fate therapeutics announces oral presentation on natural killer cell product candidate fatenk at the  ash annual meeting san diego nov   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that six abstracts highlighting the companys programs including an oral presentation on its natural read all » html pdf add to briefcase file is in briefcase oct   fate therapeutics to webcast conference call reporting third quarter  financial results on november   san diego oct   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that the company will host a conference call and live audio webcast on monday november   at  read all » html pdf add to briefcase file is in briefcase oct   fate therapeutics announces issuance of us patent protecting enhanced hematopoietic stem cell compositions protects cellular composition of lead immunotherapy product candidate protmune™ covers compositions generated using ex vivo modulation to enhance stem cell properties san diego oct   globe newswire  fate therapeutics inc nasdaqfate a biophar read all » html pdf add to briefcase file is in briefcase sep   fate therapeutics receives fda orphan drug designation for protmune™ in allogeneic hematopoietic cell transplantation san diego sept   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that the us food and drug administration fda has granted orphan drug designation for protmune read all » html pdf add to briefcase file is in briefcase sep   fate therapeutics and memorial sloan kettering cancer center launch partnership for development of offtheshelf tcell immunotherapies unite cellular immunotherapy expertise to accelerate clinical translation of offtheshelf products offering broad patient access collaboration to use engineered pluripotent cell lines to renewably generate tcell product candidates foundation read all » html pdf add to briefcase file is in briefcase aug   fate therapeutics to present at upcoming investor conferences san diego aug   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders today announced that scott wolchko president and chief executive officer will be presenting at two upcoming inves read all » html pdf add to briefcase file is in briefcase aug   fate therapeutics to present at the  wedbush pacgrow healthcare conference san diego aug   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that scott wolchko president and chief executive officer will present at the  wedbush pacgrow h read all » html pdf add to briefcase file is in briefcase aug   fate therapeutics reports second quarter  financial results opened patient enrollment in phase  clinical trial of protmune™ for prevention of acute gvhd and cmv infection ind filing for allogeneic memorylike nk cell cancer immunotherapy planned for  announced  million common stock private read all » html pdf add to briefcase file is in briefcase aug   fate therapeutics announces  million common stock private placement san diego aug   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that it has entered into a securities purchase agreement for a private placement with a selec read all » html pdf add to briefcase file is in briefcase aug   fate therapeutics to webcast conference call reporting second quarter  financial results on august   san diego aug   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that the company will host a conference call and live audio webcast on monday august   at  read all » html pdf add to briefcase file is in briefcase jul   fate therapeutics announces issuance of us patent on compositions of human induced pluripotent cells key patent covers renewable pluripotent cell source for development of offtheshelf nk and tcell immunotherapies san diego july   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapie read all » html pdf add to briefcase file is in briefcase jun   fate therapeutics announces fda fast track designation for protmune™ san diego june   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that the us food and drug administration fda has granted fast track designation for protmune͐ read all » html pdf add to briefcase file is in briefcase jun   fate therapeutics to host offtheshelf cancer immunotherapy focus session at  annual meeting of international society for stem cell research san diego june   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that it will host a focus session entitled fighting cancer with offtheshelf ipsc immunother read all » html pdf add to briefcase file is in briefcase jun   fate therapeutics announces preclinical data from immunoregulatory cd cell therapy for autoimmune diseases onetime administration of programmed cells demonstrates durable disease correction in type  diabetes mouse model toleracyte™ product candidate exhibits enhanced trafficking to the pancreas and potent regulation of autoreactive t cells in preclinical testing read all » html pdf add to briefcase file is in briefcase may   fate therapeutics appoints chris m storgard md as chief medical officer san diego may   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders today announced that chris m storgard md has joined the company as its chief medical officer  dr storgard i read all » html pdf add to briefcase file is in briefcase may   fate therapeutics announces preclinical data highlighting persistent effector function of allogeneic natural killer cell cancer immunotherapy adaptive nk cell therapy advancing toward firstinhuman clinical trial in collaboration with university of minnesota program to be presented today at innate killer summit  san diego may   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical read all » html pdf add to briefcase file is in briefcase may   fate therapeutics reports first quarter  financial results phase  clinical trial of protmune™ for prevention of acute gvhd and cmv infection to begin enrollment in mid adaptive nk cell cancer immunotherapy to be featured at innate killer summit in midmay  read all » html pdf add to briefcase file is in briefcase may   fate therapeutics to webcast conference call reporting first quarter  financial results on may   san diego may   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that the company will host a conference call and live audio webcast on monday may   at  pm read all » html pdf add to briefcase file is in briefcase apr   fate therapeutics to present at the needham  company th annual healthcare conference san diego april   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that scott wolchko president and chief executive officer will be presenting a company overvie read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics reports fourth quarter and full year  financial results protmune™ investigational new drug application for prevention of acute gvhd and cmv infection cleared by fda in january  phase  clinical trial of protmune to commence enrollment in mid data updates for all preclinical adoptive immunothera read all » html pdf add to briefcase file is in briefcase feb   fate therapeutics to webcast conference call reporting fourth quarter and full year  financial results on march   san diego feb   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders announced today that the company will host a conference call and live audio webcast on thursday march   at  read all » html pdf add to briefcase file is in briefcase feb   fate therapeutics to present preclinical data for protmune™ at  bmt tandem meetings poster presentation to highlight antitumor properties of ex vivo programmed donor t cells phase  clinical trial of protmune in mobilized peripheral blood hct to commence enrollment in mid san diego feb   globe newswire  fate therapeutics inc nasdaq read all » html pdf add to briefcase file is in briefcase feb   fate therapeutics to present at leerink partners th annual global healthcare conference san diego feb   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer and immune disorders announced today that scott wolchko president and chief executive officer will be presenting a company overview read all » html pdf add to briefcase file is in briefcase jan   fate therapeutics announces fda clearance of investigational new drug application for protmune for prevention of acute gvhd and cmv infection san diego jan   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer and immune disorders announced today the us food and drug administration fda has cleared the companys investigational new drug in read all » html pdf add to briefcase file is in briefcase jan   fate therapeutics to present at biotech showcase  san diego jan   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders announced today that scott wolchko president and chief executive officer will be presenting a c read all » html pdf add to briefcase file is in briefcase dec   fate therapeutics provides update on adoptive immunotherapy programs for hematopoietic cell transplantation supportive interim data from prohema® puma study demonstrate the therapeutic potential of programmed donor cells clinical development strategy to focus on prevention of lifethreatening complications in mobilized peripheral blood hct protmune™ to advance into phase  clinical trial for prevention of acute graftversush read all » html pdf add to briefcase file is in briefcase dec   fate therapeutics to present at oppenheimer  co th annual healthcare conference san diego dec   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders announced today that scott wolchko president and chief executive officer will be presenting at the oppenheimer  co read all » html pdf add to briefcase file is in briefcase nov   fate therapeutics to present strategy for the development of offtheshelf cancer immunotherapies at ash  san diego nov   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders announced today that it will present its strategy for developing offtheshelf cancer immunotherapeutics using its nov read all » html pdf add to briefcase file is in briefcase nov   fate therapeutics to present preclinical data for protmunetm at ash  annual meeting firstinhuman clinical trial to prevent acute graftversushost disease and severe infections planned for poster presentations to highlight preclinical findings and potential therapeutic and pharmacoeconomic value propositions in hct san diego nov   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical comp read all » html pdf add to briefcase file is in briefcase nov   fate therapeutics reports third quarter  financial results pluripotent cell platform for generating offtheshelf cancer immunotherapies to be presented at ash  annual meetingfirstinhuman clinical trial of protmune™ to prevent acute gvhd and severe infections planned for reached  of target enrollment for prohema® puma study san diego nov   globe newswire  fate therap read all » html pdf add to briefcase file is in briefcase oct   fate therapeutics to webcast conference call reporting third quarter  financial results on november   san diego oct   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders today announced that the company will host a conference call and live audio webcast on tuesday november   at  read all » html pdf add to briefcase file is in briefcase oct   fate therapeutics strengthens intellectual property position with new us patent covering induced pluripotent cell compositions san diego oct   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders announced today that the us patent and trademark office issued us patent no  on october   the c read all » html pdf add to briefcase file is in briefcase oct   fate therapeutics announces leadership transition scott wolchko a fate founder to succeed christian weyer as president and ceo effective december   additional leadership changes enhance fate executive team san diego oct   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the development of programmed cellular immunoth read all » html pdf add to briefcase file is in briefcase sep   fate therapeutics to present at september investor conferences san diego sept   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the development of programmed cellular immunotherapeutics for the treatment of severe lifethreatening diseases today announced that christian weyer md mas president and chief executive officer will be presenting a co read all » html pdf add to briefcase file is in briefcase aug   fate therapeutics to present at upcoming investor conferences san diego aug   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the development of programmed cellular immunotherapeutics for the treatment of severe lifethreatening diseases today announced that management will be presenting at two upcoming investor conferences in august wedbush pac read all » html pdf add to briefcase file is in briefcase aug   fate therapeutics reports second quarter  financial results interim data from prohema® puma study show reduction in severe infections across multiple pathogen types first pediatric subject treated in prohema® provide study of cns cellular replacement strategic research collaboration formed with juno therapeutics to identify small molecule modulators for programming car t and tcr im read all » html pdf add to briefcase file is in briefcase jul   fate therapeutics to webcast conference call reporting second quarter  financial results on august   san diego july   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe lifethreatening diseases today announced that the company will host a conference call and live audio webcast on wednesday august   at  read all » html pdf add to briefcase file is in briefcase jul   fate therapeutics appoints dr stewart abbot as vice president translational research san diego july   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe lifethreatening diseases announced today that it has named dr stewart abbot as vice president translational research effective immediately  read all » html pdf add to briefcase file is in briefcase jul   fate therapeutics and regents of the university of minnesota enter into research collaboration for translation of natural killer cell cancer immunotherapies adaptive natural killer cell therapeutics to be advanced as antibodymediated cancer therapy geneticallyengineered induced pluripotent stem cellderived natural killer cells to be developed as offtheshelf targeted immunotherapy fate therapeutics holds an exclusive option to secure all patent rights arising from collaboration  read all » html pdf add to briefcase file is in briefcase jun   fate therapeutics enters into sponsored research agreement with boston childrens hospital to develop immunoregulatory cell therapy for treatment of autoimmune diseases san diego june   globe newswire  fate therapeutics inc nasdaqfate announced today that it has entered into a twoyear sponsored research agreement with boston childrens hospital to accelerate the development of an adoptive immunoregulatory cell therapy to treat autoimmune diseases the collaboration seeks to assess the potential of read all » html pdf add to briefcase file is in briefcase may   fate therapeutics announces completion of public offering of common stock and full exercise of underwriters option to purchase additional shares san diego may   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe lifethreatening diseases today announced the closing of an underwritten public offering of  shares of its common stock which included  read all » html pdf add to briefcase file is in briefcase may   fate therapeutics announces pricing of public offering of common stock san diego may   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe lifethreatening diseases today announced the pricing of an underwritten public offering of  shares of its common stock at a public offer read all » html pdf add to briefcase file is in briefcase may   fate therapeutics announces proposed public offering of common stock san diego may   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe lifethreatening diseases today announced that it has commenced an underwritten public offering of  shares of its common stock fate ther read all » html pdf add to briefcase file is in briefcase may   fate therapeutics reports first quarter  financial results strategic research collaboration established with juno therapeutics to apply small molecule modulators for programming car and tcr immunotherapiesadditional data from ongoing phase  puma study of prohema® continue to demonstrate acceleration of and increased incidence of early neutrophil engraftmentnewlyreported immunoprotection data from  read all » html pdf add to briefcase file is in briefcase may   juno therapeutics and fate therapeutics announce strategic research collaboration to improve the therapeutic profile of engineered t cell immunotherapies seattle and san diego may   globe newswire  juno therapeutics inc nasdaqjuno and fate therapeutics inc nasdaqfate announced today that they have executed a strategic research collaboration and license agreement to identify and utilize small molecules to modulate junos geneticallyengineered t cell product candidates to improve read all » html pdf add to briefcase file is in briefcase may   fate therapeutics to webcast conference call reporting first quarter  financial results on may   san diego may   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe lifethreatening diseases today announced that the company will host a conference call and live audio webcast on thursday may   at  pm read all » html pdf add to briefcase file is in briefcase apr   fate therapeutics to present at deutsche bank th annual health care conference san diego april   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe lifethreatening diseases today announced that christian weyer md mas president and chief executive officer will present at the deutsch read all » html pdf add to briefcase file is in briefcase apr   fate therapeutics to present at th annual needham healthcare conference san diego april   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe lifethreatening diseases today announced that christian weyer md mas president and chief executive officer will present at the th ann read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics to present at the regen med investor day san diego march   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe lifethreatening diseases today announced that christian weyer md mas president and chief executive officer will present at the allianc read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics reports yearend  financial results favorable phase  interim data from ongoing puma study of prohema® in adult hematologic malignancies reported in december prohema clinical data in pediatric hematologic malignancies and rare genetic disorders expected in ind for programmed mobilized peripheral blood candidate using newlyidentified dual modulator combination planned in read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics to webcast conference call reporting fourth quarter and full year  financial results on march   san diego march   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe lifethreatening diseases today announced that the company will host a conference call and live audio webcast on thursday march   at  read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics expands and strengthens leadership team san diego march   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe lifethreatening diseases today announced that wendy levin md ms will join the company as vice president clinical development and that wal read all » html pdf add to briefcase file is in briefcase feb   fate therapeutics to present at cowen  company th annual health care conference san diego feb   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe lifethreatening diseases today announced that christian weyer md mas president and chief executive officer will present at the cowen   read all » html pdf add to briefcase file is in briefcase feb   fate therapeutics to present at the  leerink global healthcare conference san diego feb   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe lifethreatening diseases today announced that christian weyer md mas president and chief executive officer will present at the  leer read all » html pdf add to briefcase file is in briefcase jan   fate therapeutics announces key  objectives for the advancement of programmed cellular therapeutics pipeline primary endpoint readouts from adult puma and pediatric prompt studies of prohema in hematologic malignancies expected in midtopline data from pediatric provide study of prohema in rare inherited metabolic disorders expected in ind filing for new programmed mobilized peripheral blood candidate planned in  san diego jan    read all » html pdf add to briefcase file is in briefcase jan   fate therapeutics to present at biotech showcase  san diego jan   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe lifethreatening diseases today announced that christian weyer md mas president and chief executive officer will present an overview of t read all » html pdf add to briefcase file is in briefcase dec   fate therapeutics announces interim data from ongoing phase  puma study key metrics of neutrophil engraftment improved in prohema armindependent data monitoring committee supports continuation of study enrollmentfull results on primary efficacy endpoint expected in mid san diego dec   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and de read all » html pdf add to briefcase file is in briefcase dec   fate therapeutics highlights effects of nutrientrich media on ex vivo programmed cd cells sourced from umbilical cord blood san diego dec   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases will present today an overview of the effects of using its nutrientrich media nrm formulation in the ex vivo programming of cd cells sou read all » html pdf add to briefcase file is in briefcase dec   fate therapeutics unveils preclinical findings of newlyidentified small molecule modulator combination for ex vivo programming of mobilized peripheral blood san diego dec   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases released preclinical data today highlighting the pharmacological properties of ex vivo programmed hematopoietic cells sourced from mobilized p read all » html pdf add to briefcase file is in briefcase nov   fate therapeutics to present at piper jaffray th annual healthcare conference san diego nov   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases announced today that christian weyer md mas president and chief executive officer will present an overview of the companys programs read all » html pdf add to briefcase file is in briefcase nov   fate therapeutics reports third quarter  financial results phase b prompt study in pediatric hematologic malignancies open for enrollmentsecond data review in phase  puma study expected in qpresenting effects of ex vivo programming on mobilized peripheral blood at ash san diego nov   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the disc read all » html pdf add to briefcase file is in briefcase nov   fate therapeutics to webcast conference call reporting third quarter  financial results on november   san diego nov   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases today announced that the company will host a conference call and live audio webcast on tuesday november   at  pm est to report  read all » html pdf add to briefcase file is in briefcase oct   fate therapeutics to present at nomura biotechnology conference san diego oct   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases announced today that christian weyer md mas president and chief executive officer will discuss the companys programs at the nomura b read all » html pdf add to briefcase file is in briefcase sep   fate therapeutics to present at rodman  renshaw th annual global investment conference san diego sept   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases announced today that christian weyer md mas president and chief executive officer will present an overview of the companys programs  read all » html pdf add to briefcase file is in briefcase aug   fate therapeutics reports second quarter  financial results first data review in phase  puma study of prohema supports continuation of enrollment prompt and provide studies of prohema in pediatric patients to initiate in h san diego aug   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulat read all » html pdf add to briefcase file is in briefcase aug   fate therapeutics to webcast conference call reporting second quarter  financial results on august   san diego aug   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases today announced that the company will host a conference call and live audio webcast on tuesday august   at  pm edt to report it read all » html pdf add to briefcase file is in briefcase jul   fate therapeutics secures up to  million in debt financing san diego july   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases announced today that it has completed a longterm debt financing of up to  million with silicon valley bank the company has drawn down  read all » html pdf add to briefcase file is in briefcase jul   fate therapeutics announces fda clearance of ind for clinical development of prohema in inherited metabolic disorders san diego july   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases announced today that the us food and drug administration fda has cleared its investigational new drug application ind for the clinical  read all » html pdf add to briefcase file is in briefcase jun   fate therapeutics submits ind application for the clinical development of prohemar in inherited metabolic disorders san diego june   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases announced today that it has submitted an investigational new drug ind application to the us food and drug administration fda for the cl read all » html pdf add to briefcase file is in briefcase jun   fate therapeutics to highlight potential clinical applications of ex vivo hematopoietic cell modulation at th international cord blood symposium san diego june   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases today announced that potential clinical applications of its ex vivo approach to pharmacologically modulating hematopoietic cells will be prese read all » html pdf add to briefcase file is in briefcase may   fate therapeutics to present at jefferies  global healthcare conference san diego may   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases announced today that christian weyer md mas president and chief executive officer will present an overview of the companys programs  read all » html pdf add to briefcase file is in briefcase may   fate therapeutics reports first quarter  financial results phase  puma study of prohema® in adult hematologic malignancies enrolling patientsphase b prompt study of prohema in pediatric hematologic malignancies cleared by fdaind submission for study of prohema in rare genetic disorders expected in q san diego may   globe newswire  fate therapeutics inc nasdaqfate a biopharma read all » html pdf add to briefcase file is in briefcase may   fate therapeutics to webcast conference call reporting first quarter  financial results on may   san diego may   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases today announced that the company will host a conference call and live audio webcast on tuesday may   at  pm edt to report its fi read all » html pdf add to briefcase file is in briefcase apr   fate therapeutics to present at deutsche bank th annual health care conference san diego april   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases announced today that christian weyer md mas president and chief executive officer will present an overview of the company at the de read all » html pdf add to briefcase file is in briefcase apr   fate therapeutics announces fda clearance of ind amendment for clinical development of prohemar in pediatric patients san diego april   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases announced today that the us food and drug administration fda has cleared its investigational new drug application ind amendment to eva read all » html pdf add to briefcase file is in briefcase apr   fate therapeutics secures us patent for class of small molecule modulators key to the development of ipscbased therapeutics san diego april   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases announced today that the us patent and trademark office pto has issued patent no  entitled stem cell cultures the newly iss read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics reports fourth quarter and full year  financial results phase  puma study of prohema® initiated  interim data expected in hclinical trial of prohema® in lysosomal storage disorders to begin in hencouraging clinical data published highlighting the potential of ex vivo t cell modulation san diego march   globe newswire  fate therapeutics inc nasdaqfate a biopharmace read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics appoints dr robert s epstein to its board of directors san diego march   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases announced today that dr robert s epstein md has joined its board of directors dr epstein is a strategic consultant to life scien read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics commences phase  clinical trial of prohemar for the treatment of hematologic malignancies first patient enrolled in puma studyapproved for conduct at ten leading us centersinterim data expected in h san diego march   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases announced today the en read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics to webcast conference call reporting fourth quarter and full year  financial results on march   san diego march   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases today announced that the company will host a conference call and live audio webcast on monday march   at  pm edt to report it read all » html pdf add to briefcase file is in briefcase mar   fate therapeutics announces publication of its proprietary stem cell modulation platform for developing ipscbased regenerative therapeutics san diego march   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases announced today the publication of an article in the journal stem cell reports by fate scientists demonstrating highthroughput derivation of read all » html pdf add to briefcase file is in briefcase feb   fate therapeutics observes rare disease day  san diego feb   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases is joining the muscular dystrophy association mda and other advocacy organizations around the world today to observe rare disease day® read all » html pdf add to briefcase file is in briefcase feb   fate therapeutics to present at upcoming march conferences san diego feb   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases announced today that christian weyer md mas president and chief executive officer will present an overview of the companys programs read all » html pdf add to briefcase file is in briefcase feb   fate therapeutics announces observed effects of pharmacologic modulation on t cell compartment from its phase b study of prohemar san diego feb   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases announced today the release of new data on the observed effects of ex vivo pharmacologic modulation on cd t cells and immune reconstitution read all » html pdf add to briefcase file is in briefcase nov   fate therapeutics reports third quarter  financial results cleared key milestones for resumption of prohema phase  clinical trialselected wnta protein analogs for advancement into indenabling activitiesextended breadth of patent protection for hsc modulation platform san diego nov   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discove read all » html pdf add to briefcase file is in briefcase nov   fate therapeutics to webcast conference call reporting third quarter  financial results on november   san diego nov   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases today announced that the company will host a conference call and live audio webcast on wednesday november   at  pm est to repor read all » html pdf add to briefcase file is in briefcase oct   fate therapeutics announces closing of initial public offering and exercise of option to purchase additional shares san diego oct   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases today announced the closing of its previously announced initial public offering of  shares of its common stock at a public offering p read all » html pdf add to briefcase file is in briefcase oct   fate therapeutics to present at world muscle society congress san diego oct   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases announced today that its senior vice president early program development dr peter flynn phd is scheduled to present at the th interna read all » html pdf add to briefcase file is in briefcase oct   fate therapeutics inc announces pricing of initial public offering san diego oct   globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases today announced the pricing of its initial public offering of  shares of its common stock price to the public of  per share bef read all » html pdf add to briefcase file is in briefcase aug   fate therapeutics files registration statement for proposed initial public offering san diego ca – fate therapeutics inc a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators today announced that it has filed a registration statement on form s with the us securities and exchange commission “sec” relating to the proposed initial public offering of read all » html pdf add to briefcase file is in briefcase apr   fate therapeutics presents efficacy data for wntaanalog program at muscular dystrophy association  scientific conference san diego ca – fate therapeutics inc a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators announced today the presentation of preclinical data from its wnta protein analog program for the treatment of muscular dystrophy at the muscular dystrophy association mda  scientific  read all » html pdf add to briefcase file is in briefcase feb   fate therapeutics to present at cowen  co rd annual health care conference san diego ca – fate therapeutics inc a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators announced today that christian weyer md mas president and chief executive officer will present an overview of the company at the cowen  co rd annual health care conference in read all » html pdf add to briefcase file is in briefcase feb   fate therapeutics to present at th annual bio ceo  investor conference san diego ca – fate therapeutics inc a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators today announced that christian weyer md mas president and chief executive officer will be presenting a company overview at the th annual bio ceo  investor conference at   read all » html pdf add to briefcase file is in briefcase dec   fate therapeutics strengthens leadership position in the development of wntbased protein therapeutics san diego ca – fate therapeutics inc a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators announced today several advancements in its goal to develop the first wntprotein therapeutic for regenerative medicine applications after seve read all » html pdf add to briefcase file is in briefcase nov   fate therapeutics initiates phase  clinical study of prohema for the treatment of hematologic malignancies san diego ca – fate therapeutics inc a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators announced today the initiation of a randomized controlled phase  multicenter study of its investigational hematopoietic stem cell therapy pr read all » html pdf add to briefcase file is in briefcase oct   fate therapeutics appoints christian weyer as president and chief executive officer san diego ca – fate therapeutics inc announced today that christian weyer md mas has been appointed president and chief executive officer and elected to the company’s board of directors effective immediately dr weyer joins fate therapeutics after a year tenure with  read all » html pdf add to briefcase file is in briefcase jun   fate therapeutics and bd biosciences launch bd smc to improve cellular reprogramming and ips cell culture applications san diego ca  – fate therapeutics inc in collaboration with bd biosciences a segment of bd becton dickinson and company today announced the introduction of the first induced pluripotent stem cell ipscrelated product resulting from the collaboration between the two companies bd read all » html pdf add to briefcase file is in briefcase dec   fate therapeutics announces the appointment of william h rastetter as chairman and interim ceo san diego ca – fate therapeutics inc announced today that it has appointed william h rastetter phd as chairman and interim chief executive officer dr rastetter served as chief executive officer of idec pharmaceuticals from december  through november  and as chairman from may  read all » html pdf add to briefcase file is in briefcase dec   fate therapeutics announces promising data from phase b study of prohema at the  american society of hematology annual conference san diego ca – fate therapeutics inc announced today promising clinical results from a phase b trial of prohema ftenhanced umbilical cord blood as part of doubleumbilical cord blood ucb transplants in adult patients with hematologic malignancies who have undergone reduced read all » html pdf add to briefcase file is in briefcase dec   fate therapeutics secures foundational patent for ips cell programming san diego ca  – fate therapeutics inc announced today that the united states patent and trademark office has granted a patent covering compositions that are broadly utilized throughout the field of induced pluripotent stem cell ipsc technology us patent no  entitled “ read all » html pdf add to briefcase file is in briefcase nov   fate therapeutics strengthens its ipsc platform san diego california november    fate therapeutics inc announced today that the united states patent and trademark office has granted a patent covering the novel stem cell modulator commonly known as thiazovivin us patent no  entitled stem cell cultures claims th read all » html pdf add to briefcase file is in briefcase may   takeda ventures makes strategic investment in fate therapeutics osaka japan  san diego california may   – takeda pharmaceutical company limited “takeda” and fate therapeutics inc “fate” jointly announced today that takeda’s corporate venture arm takeda ventures inc palo alto california “tvi” has made an equity investment in fate  read all » html pdf add to briefcase file is in briefcase feb   fate therapeutics announces emerging data from proofofconcept ft clinical trial and receives orphan drug designation san diego ca – february   – fate therapeutics inc presented encouraging preliminary data from an ongoing phase b clinical trial of ft at the  bmt tandem meetings in honolulu hawaii abstract number  entitled “ex vivo treatment of hematopoiet read all » html pdf add to briefcase file is in briefcase feb   fate therapeutics announces encouraging clinical results and change in management san diego ca – february   – in parallel with announcing encouraging clinical data at the  bmt tandem meetings from its ongoing proofofconcept ft phase b trial fate therapeutics announced that paul a grayson who has been president  ceo since april  is  read all » html pdf add to briefcase file is in briefcase oct   fate therapeutics announces collaboration with bd to develop and commercialize induced pluripotent stem cell technology san diego ca and ottawa canada october   – fate therapeutics inc has forged a collaboration and license agreement with bd becton dickinson and company a leading global medical technology company through its bd biosciences segment for the joint development and worldwide  read all » html pdf add to briefcase file is in briefcase jun   fate therapeutics receives red herrings north america  award for advancing stem cell technology and new medicines san diego ca and ottawa canada – fate therapeutics inc announced today that the company received red herring’s north america  award a prestigious list honoring the year’s most promising private and innovative companies from the north american business region the nominees were evaluated by the red herring editorial tea read all » html pdf add to briefcase file is in briefcase may   fate therapeutics expands scientific advisory board to advance ipsc technology and stem cell modulator pipeline san diego ca and ottawa canada – fate therapeutics inc announces the appointment of six respected research leaders to the company’s scientific advisory board sab the new sab members bring deep experience and expertise in systems biology epigenetics gene regulation expression analysis and adult stem cell and developmental bi read all » html pdf add to briefcase file is in briefcase may   fate therapeutics appoints tom novak phd as vice president of research and drug discovery san diego ca and ottawa canada – fate therapeutics inc announces the appointment of tom novak phd as vice president of research and drug discovery dr novak brings to fate more than  years of experience working with large pharmaceutical companies including roche and wyeth to apply tra read all » html pdf add to briefcase file is in briefcase apr   fate therapeutics expands stem cell modulator pipeline with acquisition of verio therapeutics san diego ca and ottawa canada – fate therapeutics inc announced today a definitive agreement to acquire verio therapeutics inc a privately held biotechnology company based in ottawa ontario which is developing drug candidates targeting the activation of endogenous stem cells verio therap read all » html pdf add to briefcase file is in briefcase feb   fate therapeutics named one of the  most innovative companies in the world by mits technology review san diego ca – fate therapeutics inc announced today that the company was named as one of technology review’s  tr the first annual list of the  most innovative companies in the world the  tr companies span the field read all » html pdf add to briefcase file is in briefcase feb   fate therapeutics receives allowance of first us patent for induced pluripotent stem cell technology san diego ca – fate therapeutics inc received a notice of allowance from the united states patent and trademark office for us patent application number  entitled “methods for reprogramming somatic cells” upon issuance the patent will cover foundational induced plur read all » html pdf add to briefcase file is in briefcase dec   fate therapeutics ipsc technology awarded top industry honors for small molecule and protein reprogramming breakthroughs san diego ca – fate therapeutics inc announced today that the company’s ipsc technology platform developed with sheng ding phd has been honored as the top innovation of  by the scientist and has received the  north american technology innovation award from frost  sullivan these notable awards recognize fate ther read all » html pdf add to briefcase file is in briefcase nov   fate therapeutics closes  million series b financing la jolla ca – fate therapeutics inc announced today that it has completed a  million series b financing led by ovp venture partners joining ovp venture partners in the financing is a syndicate of corporate investors including astellas venture management genzyme ventures and a third undisclosed corporate investor the three cole read all » html pdf add to briefcase file is in briefcase oct   fate therapeutics announces creation of small molecule platform for commercial scale reprogramming la jolla ca – fate therapeutics inc announced today the generation of human induced pluripotent stem cells ipscs using a combination of small molecules that significantly improves the speed and efficiency of reprogramming the discoveries which were made by sheng ding phd under a research collaboration between fate therapeutics read all » html pdf add to briefcase file is in briefcase jul   fate therapeutics to present data on stimulation of osteogenic activity using small molecule modulators of wnt pathway la jolla ca and barcelona – fate therapeutics inc announced today the presentation of data from its research on small molecule modulators of the wnt pathway for osteoregeneration at the th annual meeting of the international society for stem cell research isscr in barcelona spain in its findings the company demonstrated that se read all » html pdf add to briefcase file is in briefcase jul   fate therapeutics granted exclusive license by the regents of the university of california to stem cell modulators for osteoregeneration la jolla ca – fate therapeutics inc announced today that it has acquired exclusive intellectual property rights covering small molecule compositions and methods for inducing bone formation from the regents of the university of california these proprietary osteogenic agents were developed by farhad parhami phd professor of medicine  read all » html pdf add to briefcase file is in briefcase page     next last   view all items  add release to briefcase facebook google linkedin twitter email rss menu about us our focus management board of directors pipeline overview immunooncology candidates fatenk engineered hncdink engineered car it cell immunoregulation candidates protmuneâ„¢ toleracyteâ„¢ science cell programming science programming cell function programming cell fate ipscs isscr annual meeting collaborations join our team career opportunities vision mission values working at fate investors overview press releases events  presentations financials  filings sec filings annual reports and proxies corporate governance stock information historical stock lookup investors faqs contact as fate therapeutics inc trades do analysts recommend you sell  the de soto edge ftse    nasdaq composite   sp    nikkei    hang seng index    the de soto edge the de soto edge news online in the news fortune brands home  security inc nysefbhs receives an update from brokers flagstar bancorp inc nysefbc receives an update from brokers in volatile markets do analysts think you should buy facebook inc nasdaqfb as fate therapeutics inc trades do analysts recommend you sell as fastenal company trades do analysts recommend you sell facebook twitter youtube instagram pinterest as fate therapeutics inc trades do analysts recommend you sell by ashley brown  in stocks  on friday  jul   pm   comments as fate therapeutics inc trades currently  analysts have their eyes on the stock whilst  of which rate it “buy”  “outperform”  “underperform”  “sell” while  “hold” individual stock ratings issued for fate are highlighted below  – broker hc wainwright rating new target  reiteration  – broker wedbush rating new target  reiteration  – broker bmo capital markets rating new target  reiteration  – broker roth capital rating new target  newcoverage  – broker leerink swann rating new target  reiteration  – broker wells fargo rating newcoverage  – broker cowen rating reiteration  – broker raymond james rating new target  newcoverage  – broker zacks rating new target  downgrade the average target price given to the stock from the most recent broker reports is  the stock decreased   during the last days session reaching  and roughly  shares were bought or sold by traders fate therapeutics inc fate therapeutics is a clinicalstage biopharmaceutical company the company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders the company’s cell therapy pipeline consists of immunooncology programs including cancer immunotherapies derived from engineered induced pluripotent cells and immunoregulatory programs including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity its lead clinical program is protmune which is a programmed immunoregulatory cell therapy the company programs immune cells such as cd cells natural killer nk cells and t cells by utilizing its cell programming approach its adoptive cell therapy programs are based on the company’s ex vivo cell programming approach which it applies to modulate the therapeutic function and direct the fate of immune cells more from reuters » receive fate therapeutics inc news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for fate therapeutics inc with marketbeatcoms free daily email newsletter recommended posts fortune brands home  security inc nysefbhs receives an update from brokers analysts reviewing fortune brands home  security inc have recently updated their recommended buysell flagstar bancorp inc nysefbc receives an update from brokers analysts reviewing flagstar bancorp inc have recently updated their recommended buysell ratings and in volatile markets do analysts think you should buy facebook inc nasdaqfb following us election volatility some analysts have updated their recommended target prices on shares as fastenal company trades do analysts recommend you sell as fastenal company trades currently  analysts have their eyes on the stock whilst  of which rate free email newsletter enter your email address below to get the latest news and analysts ratings for your stocks with marketbeats free daily email newsletter investor relations  fate therapeutics inc fate therapeutics investors we are a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies our pipeline is comprised of cellbased therapies for cancer and immune disorders our cellular immunotherapies are based on our novel ex vivo cell programming approach which we apply to modulate the therapeutic function and direct the fate of hematopoietic cells press releases may   fate therapeutics reports first quarter  financial results read all » may   fate therapeutics announces fda clearance of investigational new drug application for fatenk in advanced solid tumors read all » events  presentations may   fate therapeutics q  earnings conference call read all » apr   th annual cell  gene therapy investor day read all » stock quote price  change   high  view details delayed at least  minutes stock chart  month  month  year facebook google linkedin twitter email rss menu about us our focus management board of directors pipeline overview immunooncology candidates fatenk engineered hncdink engineered car it cell immunoregulation candidates protmuneâ„¢ toleracyteâ„¢ science cell programming science programming cell function programming cell fate ipscs isscr annual meeting collaborations join our team career opportunities vision mission values working at fate investors overview press releases events  presentations financials  filings sec filings annual reports and proxies corporate governance stock information historical stock lookup investors faqs contact